GSK to Initiate P-III ContRAst Studies of Otilimab to Treat Moderate to Severe Rheumatoid Arthritis

Shots:

• The four P-III ContRAst -1, 2, 3 & X studies will assess otilimab (90mg/150mg, SC, qw) vs PBO, tofacitinib (5mg, bid), sarilumab (200mg, SC) all in combination with MTX/ DMARDs in patients with RA, following the results of P-II BAROQUE study  
• The 1EPs & 2EPs of P-III ContRAst studies will be ACR20 @12wks. against PBO & CDAI score and HAQ-DI score and pain against PBO, tofacitinib/sarilumab and the studies will be conducted across 32 countries
• Otilimab (GSK3196165) is a mAb targeting granulocyte-macrophage colony-stimulating factor (GM-CSF), act by blocking its interaction with its cell surface receptor. In 2013, MorphoSys granted exclusive WW development and commercialization rights of Otilimab to GSK

Click here to read full press release/ article | Ref: GSK | Image: CNBC TV18